Halozyme Therapeutics (HALO) Inventory Average (2011 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Inventory Average of $166.0 million for Q1 2026, up 8.22% year-over-year from $153.4 million in Q1 2025, and down 8.37% quarter-over-quarter from $181.1 million in Q4 2025.
Halozyme Therapeutics (HALO) Inventory Average (2011 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Inventory Average for 16 consecutive years, with $166.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Inventory Average rose 8.22% year-over-year to $166.0 million; the TTM figure through Mar 2026 stood at $166.0 million (up 8.22% YoY), while the FY2025 annual figure was $159.2 million, up 18.14% from the prior year.
- Inventory Average slipped to $166.0 million in Q1 2026 per HALO's latest filing, from $181.1 million in the prior quarter.
- Across five years, Inventory Average topped out at $183.7 million in Q3 2025 and bottomed at $50.8 million in Q1 2022.
- Historically, Inventory Average has averaged $132.9 million across 5 years, with a median of $136.6 million in 2024.
- Annual changes were most pronounced in 2022 — Inventory Average dropped 14.63% — and 2023, when it surged 104.24%.
- Halozyme Therapeutics' Inventory Average stood at $101.7 million in 2022, then gained by 26.12% to $128.3 million in 2023, then rose by 6.53% to $136.6 million in 2024, then jumped by 32.57% to $181.1 million in 2025, then decreased by 8.37% to $166.0 million in 2026.
- Business Quant data shows HALO's Inventory Average at $166.0 million in Q1 2026, $181.1 million in Q4 2025, and $183.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.09 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 707.10 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 355,998.06 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 90.57 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 137.65 Mn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 146.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 146.30 Mn |
| Mar 31, 2026 | 165.97 Mn |
| Dec 31, 2025 | 181.14 Mn |
| Sep 30, 2025 | 183.65 Mn |
| Jun 30, 2025 | 173.19 Mn |
| Mar 31, 2025 | 153.36 Mn |
| Dec 31, 2024 | 136.64 Mn |
| Sep 30, 2024 | 145.36 Mn |
| Jun 30, 2024 | 163.93 Mn |
| Mar 31, 2024 | 148.07 Mn |
| Dec 31, 2023 | 128.26 Mn |
| Sep 30, 2023 | 130.66 Mn |
| Jun 30, 2023 | 119.96 Mn |
| Mar 31, 2023 | 103.82 Mn |
| Dec 31, 2022 | 101.70 Mn |
| Sep 30, 2022 | 100.45 Mn |
| Jun 30, 2022 | 72.69 Mn |
| Mar 31, 2022 | 50.83 Mn |
| Dec 31, 2021 | 54.94 Mn |
| Sep 30, 2021 | 57.27 Mn |